BioVex Group Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Employees
-
75
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$597M
BioVex Group General Information
Description
Developer of biologics for the treatment of cancer and prevention of infectious diseases. The company developed OncoVEXGM-CSF, an oncolytic vaccine that destroys cancer cells and leaves healthy and unharmed tissues and ImmunoVEXHSV2, a vaccine for genital herpes.
Contact Information
Website
www.biovex.comCorporate Office
- 34 Commerce Way
- Woburn, MA 01801
- United States
Corporate Office
- 34 Commerce Way
- Woburn, MA 01801
- United States
BioVex Group Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 04-Mar-2011 | $597M | Completed | Clinical Trials - Phase 3 | ||
| 11. Later Stage VC | 08-Jun-2010 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 11-Nov-2009 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series F) | 10-Nov-2009 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series E) | 15-Nov-2007 | Completed | Generating Revenue | |||
| 7. Mezzanine | 09-Jul-2007 | Completed | Generating Revenue | |||
| 6. IPO | 20-Oct-2006 | Cancelled | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series D) | 26-May-2005 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 03-Oct-2004 | $14.5M | $59M | Completed | Generating Revenue | |
| 3. Later Stage VC (Series B) | 03-Oct-2004 | $25.2M | $44.5M | Completed | Generating Revenue |
BioVex Group Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series F | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 18,517,457 | $0.000100 | $0.89 | $0.89 | $0.89 | 4.95% | ||
| Series A | 95,213 | $0.000100 |
BioVex Group Comparisons
Industry
Financing
Details
BioVex Group Competitors (1)
One of BioVex Group’s competitors is Sharp Therapeutics (Biotechnology), a Formerly VC-backed company based in Pittsburgh, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sharp Therapeutics (Biotechnology) | Formerly VC-backed | Pittsburgh, PA |
BioVex Group Patents
BioVex Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20060188480-A1 | Viral vectors | Active | 25-Jul-2003 | ||
| US-20100143309-A1 | Viral vectors | Active | 25-Jul-2003 | ||
| US-7981669-B2 | Viral vectors | Inactive | 25-Jul-2003 | ||
| US-8679830-B2 | Viral vectors | Inactive | 25-Jul-2003 | ||
| US-20030091537-A1 | Anticancer agents; gene coding immunomoderator cytokine protein | Active | 21-Jan-2000 | C12N7/00 |
BioVex Group Signals
BioVex Group Former Investors (31)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 180 Degree Capital | Hedge Fund | Minority | ||
| ABN AMRO Bank | Investment Bank | Minority | ||
| Avalon Ventures | Venture Capital | Minority | ||
| BMO Capital Markets | Investment Bank | Minority | ||
| Beringea | Venture Capital | Minority |
BioVex Group FAQs
-
When was BioVex Group founded?
BioVex Group was founded in 1999.
-
Where is BioVex Group headquartered?
BioVex Group is headquartered in Woburn, MA.
-
What is the size of BioVex Group?
BioVex Group has 75 total employees.
-
What industry is BioVex Group in?
BioVex Group’s primary industry is Biotechnology.
-
Is BioVex Group a private or public company?
BioVex Group is a Private company.
-
What is the current valuation of BioVex Group?
The current valuation of BioVex Group is .
-
What is BioVex Group’s current revenue?
The current revenue for BioVex Group is .
-
How much funding has BioVex Group raised over time?
BioVex Group has raised $233M.
-
Who are BioVex Group’s investors?
180 Degree Capital, ABN AMRO Bank, Avalon Ventures, BMO Capital Markets, and Beringea are 5 of 31 investors who have invested in BioVex Group.
-
Who are BioVex Group’s competitors?
Sharp Therapeutics (Biotechnology) is a competitor of BioVex Group.
-
When was BioVex Group acquired?
BioVex Group was acquired on 04-Mar-2011.
-
Who acquired BioVex Group?
BioVex Group was acquired by Amgen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process